Previous studies have shown that cell lines overexpressing HER2 and HER2-positive breast cancer have an activated PI3K/AKT pathway [10], however HER2 activation also activates the MEK/MAPK pathway [11]. This evidence concerns the gene ERBB2 and breast carcinoma.